Search Results

Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stage Strengthened balance sheet by extinguishing $32 million in debt Subsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully implanted cochlear implant

Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)

• Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials • Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue Systems

Imagine a day alongside leaders advancing oligonucleotide and peptide therapeutics. The Oligonucleotides & Peptides Xchange San Francisco 2026 brings together senior leaders for focused discussions on discovery, delivery, and manufacturing. Through roundtables, presentations, and 1:1 meetings, gain practical insights and valuable connections. Registration is complimentary for qualified attendees.

This novel whole-body insulin-sensitizing approach is designed to address insulin resistance independent of weight loss

Join senior industry leaders at the Antibody Therapeutics Xchange San Francisco 2026 for a highly curated day of focused discussion across target selection, lead optimisation, multispecifics, and ADC design. Through expert-led roundtables, presentations, and 1:1 meetings, this invitation-only forum enables meaningful collaboration and practical insight exchange. Registration is complimentary for qualified attendees.

Join senior experts shaping the future of biologics production at the Antibody Manufacturing Xchange San Francisco 2026. This invitation-only meeting brings together pharma and biotech leaders to tackle key manufacturing challenges through roundtables, presentations, and 1:1 meetings. Taking place 1st September 2026. Complimentary registration for qualified attendees.

Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the company at the heart of former CDER Director George Tidmarsh’s exit from the FDA.

The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.